Loading
A phase 3 trial testing Azenosertib in ovarian cancer, now recruiting.
A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression is a phase 3 interventional study registered as NCT07546500, led by K-, Beta with European Network of Gynaecological Oncological Trial Groups (ENGOT) and GOG Foundation, and recruiting on the registry. Official title: A Randomised, Open-Label Phase 3 Study of Azenosertib Versus Investigator's Choice of Chemotherapy in Platinum-Resistant High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers Positive for Cyclin E1 Protein Expression. Planned enrolment is 420 participants (estimated). The study started in 2026-04-17 and primary completion is expected in 2028-05-31. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Azenosertib, High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Shares High-grade serous ovarian cancer, Platinum-resistant ovarian cancer, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/